|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 6 (September 15), 1998:
pp. 1941-1949
IL-2 Adenovector-Transduced Autologous Tumor Cells Induce Antitumor
Immune Responses in Patients With Neuroblastoma
Laura Bowman,
Michael Grossmann,
Donna Rill,
Michael Brown,
Wan-yun Zhong,
Barbara Alexander,
Thasia Leimig,
Elaine Coustan-Smith,
Dario Campana,
Jesse Jenkins,
Diane Woods,
Geoffrey Kitchingman,
Elio Vanin, and
Malcolm Brenner
From the Departments of Hematology-Oncology, Pathology, and Virology,
St Jude Children's Research Hospital, Memphis, TN; and the Department
of Pediatrics, University of Tennessee, Memphis College of Medicine,
Memphis, TN.
In many different murine models, the immunogenicity of tumor cells
can be increased by transduction with a range of immunostimulatory genes, inducing an immune response that causes regression of
pre-existing unmodified tumor cells. To investigate the relevance of
these animal models to pediatric malignancy, we used autologous
unirradiated tumor cells transduced with an adenovirus-IL-2 to immunize
10 children with advanced neuroblastoma. In a dose-escalation study, we
found that this tumor immunogen induced a moderate local inflammatory response consisting predominantly of CD4+ T lymphocytes,
and a systemic response, with a rise in circulating CD25+
and DR+ CD3+ T cells. Patients also made a
specific antitumor response, manifest by an IgG antitumor antibody and
increased cytotoxic T-cell killing of autologous tumor cells.
Clinically, five patients had tumor responses after the tumor immunogen
alone (one complete tumor response, one partial response, and three
with stable disease). Four of these five patients were shown to have
coexisting antitumor cytotoxic activity, as opposed to only one of the
patients with nonresponsive disease. These results show a promising
correlation between preclinical observations and clinical outcome in
this disease, and support further exploration of the approach for
malignant diseases of children.
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
X. Yan, B. D. Johnson, and R. J. Orentas
Induction of a VLA-2 (CD49b)-Expressing Effector T Cell Population by a Cell-Based Neuroblastoma Vaccine Expressing CD137L
J. Immunol.,
October 1, 2008;
181(7):
4621 - 4631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Rousseau, E. Biagi, A. Dutour, E. S. Yvon, M. P. Brown, T. Lin, Z. Mei, B. Grilley, E. Popek, H. E. Heslop, et al.
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation
Blood,
February 15, 2006;
107(4):
1332 - 1341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hirschmann-Jax, A. E. Foster, G. G. Wulf, J. G. Nuchtern, T. W. Jax, U. Gobel, M. A. Goodell, and M. K. Brenner
A distinct "side population" of cells with high drug efflux capacity in human tumor cells
PNAS,
September 28, 2004;
101(39):
14228 - 14233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rodolfo, R. Luksch, E. Stockert, Y.-T. Chen, P. Collini, T. Ranzani, C. Lombardo, P. Dalerba, L. Rivoltini, F. Arienti, et al.
Antigen-Specific Immunity in Neuroblastoma Patients: Antibody and T-Cell Recognition of NY-ESO-1 Tumor Antigen
Cancer Res.,
October 15, 2003;
63(20):
6948 - 6955.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Pertl, H. Wodrich, J. M. Ruehlmann, S. D. Gillies, H. N. Lode, and R. A. Reisfeld
Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma
Blood,
January 15, 2003;
101(2):
649 - 654.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Dotti, B. Savoldo, P. Yotnda, D. Rill, and M. K. Brenner
Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40+ and CD40- plasmacytoma cells
Blood,
June 17, 2002;
100(1):
200 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Adachi, P. N. Reynolds, M. Yamamoto, M. Wang, K. Takayama, S. Matsubara, T. Muramatsu, and D. T. Curiel
A Midkine Promoter-based Conditionally Replicative Adenovirus for Treatment of Pediatric Solid Tumors and Bone Marrow Tumor Purging
Cancer Res.,
November 1, 2001;
61(21):
7882 - 7888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Balicki, R. A. Reisfeld, U. Pertl, E. Beutler, and H. N. Lode
Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma
PNAS,
September 29, 2000;
(2000)
210382997.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. K. Sarkar and J. G. Nuchtern
Lysis of MYCN-amplified Neuroblastoma Cells by MYCN Peptide-specific Cytotoxic T Lymphocytes
Cancer Res.,
April 1, 2000;
60(7):
1908 - 1913.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Brenner
Gene Transfer by Adenovectors
Blood,
December 15, 1999;
94(12):
3965 - 3967.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Balicki, R. A. Reisfeld, U. Pertl, E. Beutler, and H. N. Lode
Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma
PNAS,
October 10, 2000;
97(21):
11500 - 11504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
